Afatinib [60], marketed as Gilotrif and classified as an anilinequinazoline derivative, is a member of the tyrosine kinase inhibitor family and is commonly administered orally for the treatment of NSCLC cases with EGFR mutations. Here, EGFR is linked to non-small cell lung carcinoma.